167 related articles for article (PubMed ID: 19277881)
1. Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway.
Martin RM; Vatten L; Gunnell D; Romundstad P; Nilsen TI
Cancer Causes Control; 2009 Sep; 20(7):1181-92. PubMed ID: 19277881
[TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome but not obesity measures are risk factors for accelerated age-related glomerular filtration rate decline in the general population.
Stefansson VTN; Schei J; Solbu MD; Jenssen TG; Melsom T; Eriksen BO
Kidney Int; 2018 May; 93(5):1183-1190. PubMed ID: 29395334
[TBL] [Abstract][Full Text] [Related]
3. Metabolic syndrome and risk of mortality in middle-aged versus elderly individuals: the Nord-Trøndelag Health Study (HUNT).
Hildrum B; Mykletun A; Dahl AA; Midthjell K
Diabetologia; 2009 Apr; 52(4):583-90. PubMed ID: 19194692
[TBL] [Abstract][Full Text] [Related]
4. Physical activity and cardiovascular risk factors at menopause: the Nord-Trøndelag health study.
Gudmundsdottir SL; Flanders WD; Augestad LB
Climacteric; 2013 Aug; 16(4):438-46. PubMed ID: 23347190
[TBL] [Abstract][Full Text] [Related]
5. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
Hammarsten J; Högstedt B
Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
[TBL] [Abstract][Full Text] [Related]
6. Metabolic syndrome and risk of incident psoriasis: prospective data from the HUNT Study, Norway.
Snekvik I; Nilsen TIL; Romundstad PR; Saunes M
Br J Dermatol; 2019 Jan; 180(1):94-99. PubMed ID: 29904911
[TBL] [Abstract][Full Text] [Related]
7. Midlife metabolic factors and prostate cancer risk in later life.
Dickerman BA; Torfadottir JE; Valdimarsdottir UA; Wilson KM; Steingrimsdottir L; Aspelund T; Batista JL; Fall K; Giovannucci E; Sigurdardottir LG; Tryggvadottir L; Gudnason V; Markt SC; Mucci LA
Int J Cancer; 2018 Mar; 142(6):1166-1173. PubMed ID: 29114858
[TBL] [Abstract][Full Text] [Related]
8. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer.
Hammarsten J; Högstedt B
Eur J Cancer; 2005 Dec; 41(18):2887-95. PubMed ID: 16243513
[TBL] [Abstract][Full Text] [Related]
9. Informativeness of indices of blood pressure, obesity and serum lipids in relation to ischaemic heart disease mortality: the HUNT-II study.
Mørkedal B; Romundstad PR; Vatten LJ
Eur J Epidemiol; 2011 Jun; 26(6):457-61. PubMed ID: 21461943
[TBL] [Abstract][Full Text] [Related]
10. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia.
Hammarsten J; Högstedt B
Blood Press; 1999; 8(1):29-36. PubMed ID: 10412880
[TBL] [Abstract][Full Text] [Related]
11. Metabolic syndrome and esophageal and gastric cancer.
Lin Y; Ness-Jensen E; Hveem K; Lagergren J; Lu Y
Cancer Causes Control; 2015 Dec; 26(12):1825-34. PubMed ID: 26450604
[TBL] [Abstract][Full Text] [Related]
12. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study.
Agnoli C; Berrino F; Abagnato CA; Muti P; Panico S; Crosignani P; Krogh V
Nutr Metab Cardiovasc Dis; 2010 Jan; 20(1):41-8. PubMed ID: 19361966
[TBL] [Abstract][Full Text] [Related]
13. The association of weight gain during adulthood with prostate cancer incidence and survival: a population-based cohort.
Chamberlain C; Romundstad P; Vatten L; Gunnell D; Martin RM
Int J Cancer; 2011 Sep; 129(5):1199-206. PubMed ID: 21064096
[TBL] [Abstract][Full Text] [Related]
14. Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway.
Martin RM; Vatten L; Gunnell D; Romundstad P; Nilsen TI
Int J Cancer; 2008 Oct; 123(8):1924-8. PubMed ID: 18661522
[TBL] [Abstract][Full Text] [Related]
15. Serum lipids and anthropometric factors related to the prevalence of intermittent claudication.
Jensen SA; Vatten LJ; Nilsen TI; Romundstad PR; Myhre HO
Eur J Vasc Endovasc Surg; 2005 Dec; 30(6):582-7. PubMed ID: 16023385
[TBL] [Abstract][Full Text] [Related]
16. Comparison of anthropometric measurements in children to predict metabolic syndrome in adolescence: analysis of prospective cohort data.
Wicklow BA; Becker A; Chateau D; Palmer K; Kozyrskij A; Sellers EA
Int J Obes (Lond); 2015 Jul; 39(7):1070-8. PubMed ID: 25869598
[TBL] [Abstract][Full Text] [Related]
17. Calculated fast-growing benign prostatic hyperplasia--a risk factor for developing clinical prostate cancer.
Hammarsten J; Högstedt B
Scand J Urol Nephrol; 2002; 36(5):330-8. PubMed ID: 12487736
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure and risk of prostate cancer: Cohort Norway (CONOR).
Martin RM; Vatten L; Gunnell D; Romundstad P
Cancer Causes Control; 2010 Mar; 21(3):463-72. PubMed ID: 19949849
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years.
Lund Håheim L; Wisløff TF; Holme I; Nafstad P
Am J Epidemiol; 2006 Oct; 164(8):769-74. PubMed ID: 16952929
[TBL] [Abstract][Full Text] [Related]
20. Age-specific prevalence of the metabolic syndrome defined by the International Diabetes Federation and the National Cholesterol Education Program: the Norwegian HUNT 2 study.
Hildrum B; Mykletun A; Hole T; Midthjell K; Dahl AA
BMC Public Health; 2007 Aug; 7():220. PubMed ID: 17727697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
